On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib/II clinical study to evaluate the combination of Cadonilimab (CTLA-4/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.
The primary endpoints of the study include safety, assessed by the incidence of adverse events and serious adverse events, as well as overall response rate (ORR). Secondary outcomes will evaluate pharmacokinetics, anti-drug antibodies, progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and time to response (TTR).
Currently, neither Envafolimab nor Cadonilimab has been approved for the treatment of pancreatic cancer. According to the PharmaCube database, Akeso Biopharma has previously launched a Phase II clinical study (NCT06491472) investigating Envafolimab in combination with chemoradiotherapy for pancreatic cancer, along with several Phase II studies of Cadonilimab as monotherapy and in combination with other agents for the same indication (NCT06532617, NCT06153368, CTR20230810).- Flcube.com
